Market cap
$2,146 Mln
Revenue (TTM)
$512 Mln
P/E Ratio
13.7
P/B Ratio
5.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 8.65 | 1.98 | 8.04 | 35.02 | 54.54 |
| EBIT | -9.40 | 27.97 | 45.17 | 149.89 | 41.61 |
| Net Profit | -16.56 | 10.53 | -19.13 | 83.64 | 33.84 |
| EPS | -13.07 | 19.30 | -17.05 | 77.64 | 24.61 |
| Book Value | -- | -- | 37.91 | 37.73 | 16.47 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| 22.90 | -6.79 | 43.98 | 37.20 | 32.75 |
| Net Margin
| -- | -66.82 | 32.98 | -- | -- |
| Return on equity
| 32.51 | -1.98 | 38.16 | 35.56 | 81.65 |
| Return on Capital
| 25.30 | 3.73 | -- | 29.73 | 55.86 |
| Return on Assets
| 22.14 | 3.14 | 24.25 | 26.40 | 48.34 |
| Debt to Equity (x)
| -- | -- | 0.47 | 0.17 | 0.24 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
--
|
29.73
|
55.86
|
-9.69
|
-23.94
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
38.16
Higher than Peers by 19.19
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
38.16
|
35.56
|
81.65
|
-19.67
|
-44.96
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
ROA
24.25
Higher than Peers by 21.40
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
24.25
|
26.40
|
48.34
|
-8.33
|
-21.10
|
|
Peer Median
|
2.86
|
--
|
--
|
--
|
--
|
EBIT Margin
43.98
Higher than Peers by 28.16
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
43.98
|
37.20
|
32.75
|
-1.24
|
-30.26
|
|
Peer Median
|
15.82
|
--
|
--
|
--
|
--
|
Net Margin
32.98
Higher than Peers by 24.75
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
32.98
|
28.80
|
46.35
|
-10.94
|
-44.89
|
|
Peer Median
|
8.23
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
8.04
Lower than Peers by 0.02
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
8.04
|
0.20
|
0.65
|
0.68
|
0.90
|
|
Peer Median
|
8.05
|
--
|
--
|
--
|
--
|
EBIT Growth
45.17
Higher than Peers by 36.91
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
45.17
|
35.89
|
4,447.57
|
93.11
|
20.42
|
|
Peer Median
|
8.26
|
--
|
--
|
--
|
--
|
Net Profit Growth
-19.13
Lower than Peers by 26.86
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
-19.13
|
-25.67
|
800.00
|
57.15
|
8.02
|
|
Peer Median
|
7.73
|
--
|
--
|
--
|
--
|
EPS Growth
-17.05
Lower than Peers by 27.45
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
-17.05
|
-0.25
|
7.43
|
0.62
|
0.18
|
|
Peer Median
|
10.39
|
--
|
--
|
--
|
--
|
Book Value Growth
10.61
Higher than Peers by 5.74
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
10.61
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.87
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.47
Lower than Peers by 0.12
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
0.47
|
0.17
|
0.24
|
1.05
|
1.02
|
|
Peer Median
|
0.59
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
0.01
|
0.01
|
0.00
|
0.01
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
6.97
Higher than Peers by 5.32
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
6.97
|
6.71
|
5.97
|
5.16
|
6.89
|
|
Peer Median
|
1.65
|
--
|
--
|
--
|
--
|
Quick Ratio
3.81
Higher than Peers by 2.61
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
3.81
|
3.74
|
2.90
|
1.69
|
2.73
|
|
Peer Median
|
1.20
|
--
|
--
|
--
|
--
|
Interest Coverage
25.53
Higher than Peers by 20.76
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
25.53
|
26.69
|
10.02
|
-0.13
|
-2.42
|
|
Peer Median
|
4.77
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
26.98
Higher than Peers by 5.71
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
26.98
|
31.05
|
11.72
|
10.62
|
10.06
|
|
Peer Median
|
21.27
|
--
|
--
|
--
|
--
|
Asset Turnover
0.74
Higher than Peers by 0.34
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
0.74
|
0.92
|
1.04
|
0.76
|
0.49
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
--
|
74.61
|
33.15
|
30.36
|
52.25
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
--
|
316.43
|
302.88
|
362.70
|
442.68
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
--
|
35.90
|
31.67
|
31.17
|
39.44
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
--
|
355.14
|
304.36
|
361.90
|
455.49
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
13.69
Lower than Peers by 24.22
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
13.69
|
30.27
|
21.33
|
-36.17
|
-11.94
|
|
Peer Median
|
37.91
|
--
|
--
|
--
|
--
|
Price / Book Value
5.26
Lower than Peers by 2.43
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
5.26
|
9.32
|
12.08
|
7.55
|
5.18
|
|
Peer Median
|
7.69
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.56
|
--
|
--
|
--
|
--
|
EV/EBITDA
9.51
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
9.51
|
22.44
|
28.41
|
217.08
|
-21.64
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
2,146
Lower than Peers by 375
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ADMA Biologics (ADMA)
|
2,146
|
--
|
--
|
--
|
--
|
|
Peer Median
|
2,521
|
--
|
--
|
--
|
--
|